NCT01221584已完成不适用
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines
研究概览
简要总结
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be 18 years of age or older of either gender or race.
- •Subject must provide informed consent and comply with the survey procedures.
- •Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
排除标准
- •Subjects who are unwilling or unable to provide informed consent
结局指标
主要结局
Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines
时间窗: 1 visit - 1-3 days
次要结局
- Establish the proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines in the sub-population patients with fasting triglycerides >200 mg/dL (2.26mmol/L)(1 visit - 1-3 days)
- Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Russian guidelines in the following sub-populations: Primary/secondary prevention patients, Patients with metabolic syndrome(1 visit - 1-3 days)
- Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the FJETF/ NCEP ATP III guidelines, in all population and in Primary/secondary prevention patients, Patients with metabolic syndrome(1 visit - 1-3 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)DyslipidaemiaNCT02230241AstraZeneca2,700
已完成
不适用
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf StatesHypercholesterolemiaNCT01031277AstraZeneca1,000
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01025388AstraZeneca4,053
已完成
不适用
Study of Undertreatment of Patients With Dyslipidemia in BulgariaDyslipidemiaNCT01075594AstraZeneca2,500
已完成
不适用
Pan-European Survey on the Under Treatment of HypercholesterolemiaHypercholesterolemiaNCT00542867AstraZeneca6,500